Mirati Therapeutics (MRTX) is Reiterated by Wedbush to Outperform, Lowers Price Target to $ 29

Mirati Therapeutics (MRTX) was Reiterated by Wedbush to “Outperform” while Lowering the Price Target of the company shares to $ 29 from a previous price target of $41 . Wedbush advised their investors in a research report released on May 24, 2016.

Many Wall Street Analysts have commented on Mirati Therapeutics. Shares were Reiterated by Wedbush on May 9, 2016 to “Outperform” and Lowered the Price Target to $ 41 from a previous price target of $45 .Sun Trust Rbsn Humphrey Initiated Mirati Therapeutics on Mar 2, 2016 to “Buy”, Price Target of the shares are set at $32.

Mirati Therapeutics opened for trading at $15.65 and hit $16.2358 on the upside on Friday, eventually ending the session at $16, with a gain of 2.96% or 0.46 points. The heightened volatility saw the trading volume jump to 1,71,699 shares. Company has a market cap of $318,512 M.

In a different news, on Jan 19, 2016, Mark J Gergen (Executive VP, COO) sold 10,000 shares at $25.92 per share price. According to the SEC, on May 27, 2015, Jamie Christensen (SVP & Chief Scientific Officer) sold 4,750 shares at $28.07 per share price.

Mirati Therapeutics

Leave a Reply

Mirati Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Mirati Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.